BioNTech to Establish Regional Headquarters for Southeast Asia and First mRNA Manufacturing Facility in Singapore
Planned state-of-the-art manufacturing site will support global supply of mRNA-based vaccines and therapeutics
Advertisement
BioNTech SE announced plans to expand its global footprint to Asia with the establishment of its Regional Headquarters for southeast Asia in Singapore. In addition to selecting Singapore as its future regional headquarters, BioNTech plans to establish a fully integrated mRNA manufacturing facility in Singapore with support from the Singapore Economic Development Board. The new facility will provide regional and global supply capacity of BioNTech’s growing pipeline of mRNA-based product candidates, as well as a rapid response production capability for southeast Asia to address potential pandemic threats.
BioNTech to establish first regional hub in Asia Pacific region in Singapore (symbolic image).
Photo by Swapnil Bapat on Unsplash
In line with BioNTech’s mission to develop next-generation immunotherapies to improve the health of individuals worldwide, the new mRNA manufacturing facility will leverage cutting-edge manufacturing and digital infrastructure. It will be equipped to produce a range of novel mRNA vaccines and therapeutics for infectious diseases and cancer. The envisioned site will bring highly automated and end-to-end mRNA production capabilities across drug substance, drug product and fill-and-finish, with an estimated annual capacity of several hundred of million doses of mRNA-based vaccines depending on the specific vaccine.
BioNTech plans to open its Singapore office and initiate construction of the manufacturing facility in 2021, subject to planning approval. The Company anticipates that the site could be operational as early as 2023 and will create up to 80 jobs in Singapore.
“Having multiple nodes in our production network is an important strategic step in building out our global footprint and capabilities. With this planned mRNA production facility, we will increase our overall network capacity and expand our ability to manufacture and deliver our mRNA vaccines and therapies to people around the world,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “Singapore provides an excellent business climate, growing biotechnology industry and rich talent base. We would like to thank Singapore’s Economic Development Board who has been very supportive throughout our planning process and we look forward to contributing our technology and expertise to the development of the biotechnology industry in Singapore and this region.”
“We strongly welcome BioNTech’s plan to establish its mRNA manufacturing facility and regional headquarters in Singapore. The investment will enable Singapore to develop capabilities in an important new therapeutic modality as part of the strategy to grow our biopharmaceutical industry,” said Dr. Beh Swan Gin, Chairman, EDB. “In particular, BioNTech’s mRNA manufacturing facility will contribute significantly to the region’s ability to address future pandemic threats.”
Following the establishment of its U.S. Headquarters in Cambridge, MA in 2020, the establishment of BioNTech’s southeast Asia Headquarters represents a key milestone in the Company’s international expansion.
Other news from the department business & finance
Most read news
More news from our other portals
Last viewed contents
Rentschler Biopharma joins forces with Ikarovec to accelerate novel gene therapies - Ikarovec is developing novel gene therapies to treat serious, but common eye diseases
The Linde Group and Algenol Biofuels agree to cooperate in CO2 and O2 management for biofuel production from algae
RNA Healer receives around one million euros for the development of a liver fibrosis therapy - MHH project wins start-up funding competition organised by Lower Saxony research incubator Institute for Biomedical Translation Lower Saxony.
Development of novel proteasome inhibitors for treating cancer, inflammatory and autoimmune disorders - Launch of Start-up QLi5 Therapeutics
Biomass for biofuels, biochemicals will more than triple to 3.7 billion tons in 2030
Thianthrenium chemistry allows for reactivity switch of a nucleophilic amino acid into a versatile intermediate - Useful and broadly applicable tool in the field of chemical biology
U.S. Department Of Defense selects Applied Biosystems for development of instrument system to identify infectious diseases
NLS Pharma acquires a portfolio of strategic patents - Critical step in the novel development of a potential non-amphetaminic stimulant for ADHD
